Intelligent Computers, Life Extension, and the Reconfiguration of Human Conditions

Published on: 7 April 2026
Updated: 6 November 2026
Type: Essay
Reading time: 54 min read
Language: en

Translated from the Portuguese original Computadores Inteligentes, Extensão de Vida e a Reconfiguração das Condições Humanas

Preface: The Oldest Problem and the Newest Tool

There is a civilizational paradox that George Church, professor of genetics at Harvard and one of the architects of the Human Genome Project, articulates with disarming clarity: if we could choose only one technology to develop, we should choose the one that gives us more time to develop all the others. Reversing aging, on this logic, is not a vanity project or science fiction — it is the most fundamental rational meta-investment a technological civilization can make. And, for the first time in history, artificial intelligence is turning this philosophical argument into a computationally tractable research program.

This essay examines, with technical rigor and conceptual ambition, the convergence between artificial intelligence and the science of longevity. It is not an exercise in naive futurism. What is at stake is a deep reconfiguration of biology as a computational discipline — a transition that has already produced concrete results (AlphaFold, deep-learning-based epigenetic clocks, virtual screening of trillions of molecules) and that promises, in the coming decades, to radically transform the human relationship with aging, disease and death.

The central argument is as follows: AI is not merely an auxiliary tool for the biology of longevity — it is the condition of possibility for the field to overcome the experimental, computational and epistemic bottlenecks that have limited it for decades. Without AI, the combinatorial complexity of biological systems makes longevity engineering practically intractable. With AI, the solution space becomes navigable.

I. The Informational Theory of Aging: From Shannon to Sinclair

1.1 Aging as Loss of Epigenetic Information

David Sinclair, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research, proposed what he calls the “Information Theory of Aging.” The thesis, grounded in more than two decades of research on sirtuins, NAD+ metabolism and cellular reprogramming, can be summarized as follows: aging is not primarily caused by mutations in DNA (the digital information of the genome), but by the progressive degradation of epigenetic information (the analog information that controls which genes are expressed in each cell type).

The analogy Sinclair uses is that of a compact disc: DNA is the digital information recorded on the disc; aging is scratches on the surface that prevent correct reading. The underlying data remain intact — what is lost is the ability to access them. If this is correct, then aging is, in principle, reversible: it is enough to “polish” the disc, restoring the epigenetic patterns of DNA methylation to a younger state.

This is not a purely theoretical proposition. In 2020, Sinclair and collaborators published in Nature a study demonstrating that ectopic expression of three Yamanaka factors (Oct4, Sox2 and Klf4 — the OSK trio) in the retinal ganglion cells of mice restored youthful DNA methylation patterns, promoted axonal regeneration after injury and reversed vision loss in both glaucoma models and aged mice. The study demonstrated something remarkable: mammalian tissues retain a record of juvenile epigenetic information that can be accessed to restore tissue function.

In 2023, the team published in Cell evidence that epigenetic changes are a primary cause of aging in mammals — not merely a correlate. Using the ICE (Inducible Changes to the Epigenome) model, the researchers accelerated and reversed the effects of aging in mice by manipulating epigenetic information. In non-human primates, the approach restored vision in aged monkeys.

1.2 Where AI Comes In: The Problem of Combinatorial Complexity

The question the Information Theory immediately raises is: how can we restore epigenetic patterns safely, efficiently and at scale in humans? The answer involves a combinatorial explosion that dramatically exceeds human capacity for analysis.

The human epigenome contains approximately 28 million CpG sites, each of which can be methylated or demethylated, with patterns varying across cell types, developmental stages and pathological states. The Yamanaka factors (OSK) activate hundreds of other genes, and under certain circumstances can revert cells to a primitive stem-cell state — a significant oncogenic risk. The question of which factors to use, in what doses, for how long, in which tissues, and with what safety control mechanisms, constitutes a multi-objective optimization problem of extreme dimensionality.

It is precisely here that artificial intelligence becomes indispensable. Sinclair reported that, using AI-based techniques, his team can now carry out in months experiments that in the past would have required hundreds of thousands of years. Trillions of molecules have entered the virtual screening pipeline. AI is identifying molecular alternatives to the gene therapy for partial cellular reprogramming — alternatives that could come in the form of a pill.

If all goes well with the research, Sinclair projects that pills containing AI-identified molecules capable of reversing biological age could be available within a decade. Gene therapy based on partial cellular reprogramming, not yet widely available to humans, could cost about two million dollars. The pill alternatives, made feasible by AI, would represent a radical democratization.

II. Synthetic Biology and Genomic Engineering: George Church’s Program

2.1 From Reading to Writing the Genome

If Sinclair represents the epigenetic strand of longevity, George Church represents the strand of total genomic engineering. Church, whose Harvard laboratory has already co-founded about 50 biotechnology companies, approaches aging with the mindset of an operating-systems engineer: it is not enough to fix one subsystem — you have to deal with every aspect. Solving half of the pathological pathways of aging will probably buy only a few years. The approach has to be holistic.

Church and his team have developed applications that include new methods for creating organs for transplant, gene therapies for reversing aging, and gene drives to eliminate diseases such as Lyme disease and malaria. His work on adeno-associated vectors (AAV) engineered to evade innate and inflammatory immune responses, published in Science Translational Medicine in 2021, opened the possibility of less immunogenic gene therapies using TLR9-edited viruses.

Church’s vision is more radical than Sinclair’s in one fundamental respect: he does not limit himself to restoring epigenetic patterns, but proposes the active rewriting of the genome. The concept of “genetic recoding” involves altering cells or entire organisms at the DNA level so deeply that viruses cannot infect them and use their cells’ ribosomal translation machinery. With enough changes to the translation apparatus and the codons of a host cell, a virus probably cannot evolve to compensate. The gap between the expectations of its evolutionary program and the new translational environment of the engineered cells may simply be too large to adapt to.

2.2 Combinatorial Gene Therapies for Aging

Church and collaborators are addressing the hallmarks of aging — genomic instability, epigenetic alterations, loss of proteostasis, among others — through the delivery of genetic instructions for the production of growth factors, initially tested in dogs. The choice of canine models is strategic: dogs share many of the same environmental exposures as humans, and their shorter life cycles allow faster evaluation of efficacy.

But the most relevant aspect for this essay is the explicit relationship Church establishes between AI and synthetic biology. In recent interviews, Church identifies the following convergences as transformative: orders-of-magnitude reductions in the cost of DNA sequencing and synthesis; precise gene-editing tools like CRISPR; AlphaFold-type AIs; and the ability to run massively parallel, multiplexed experiments. These improvements, Church argues, put humanity on the verge of massive gains in de-aging, de-extinction and biobots that combine the best of human and natural engineering.

Church’s approach to the problem of brain aging — the hardest of all — exemplifies his audacious engineering. Even while acknowledging that the brain does not make significant use of stem cells, he proposes the artificial introduction of stem cells that could integrate into neuronal circuits, learn those circuits and gradually replace the aging cells — a neuronal “Ship of Theseus” that maintains connections and memories while renewing the material substrate. Fundamental experiments, Church argues, need to be carried out before the real difficulty of this problem can be estimated. Often, there are low-hanging fruits that people simply consider unlikely.

2.3 The Genomics of Centenarians and Supercentenarians

A recent 2025 study from Church’s laboratory — “Genetic Signatures of Exceptional Longevity” — conducted a comprehensive analysis of single-nucleotide polymorphisms (SNPs) in coding regions of centenarians and supercentenarians. This type of GWAS (Genome-Wide Association Study) analysis is precisely the domain where machine learning and deep learning techniques offer decisive advantages over traditional statistical methods.

The genomic complexity of exceptional longevity is not reducible to large-effect variants in a handful of genes. It is the result of epistatic interactions among hundreds or thousands of variants, modulated by environmental factors. Mapping this combinatorial space requires deep neural networks capable of detecting nonlinear patterns in high-dimensional data — exactly the kind of problem for which modern AI was optimized.

III. AlphaFold and the Revolution in Computational Structural Biology

3.1 From 50 Years of Frustration to a Revolution in 5

In 2020, DeepMind’s AlphaFold 2 solved the problem of protein structure prediction — a challenge that had resisted half a century of computational and experimental effort. In 2024, the system and its creator, Demis Hassabis, received the Nobel Prize in Chemistry. But the significance of AlphaFold for longevity goes far beyond academic recognition.

The AlphaFold Protein Database, containing more than 200 million protein structure predictions, has been used by more than 3 million researchers in more than 190 countries. More than 30% of AlphaFold-related research focuses on better understanding diseases. The system represented what would have taken hundreds of millions of years to solve experimentally — compressed into a freely accessible database.

AlphaFold 3, released in May 2024, dramatically expanded the scope: beyond proteins, the model predicts the structure and interactions of DNA, RNA, ligands (the small molecules that make up most drugs), ions and modified residues. It can generate joint 3D structures of entire molecular complexes, allowing a holistic view of how a potential pharmacological molecule binds to its target protein. On the PoseBusters benchmark, AlphaFold 3 showed 50% greater accuracy than the best traditional methods for protein-ligand interaction predictions, becoming the first AI system to outperform physics-based tools for biomolecular structure prediction.

3.2 Isomorphic Labs and the Next Generation

Isomorphic Labs, an AI drug discovery company founded in 2021 as a spin-off of DeepMind, developed a unified drug design engine that aims to dramatically change how new medicines are designed. In February 2026, Nature reported that the company announced an even more powerful proprietary model — described by independent scientists as equivalent to an “AlphaFold 4” — keeping the innovation as exclusive property.

In parallel, the open-source ecosystem has advanced significantly. In 2025, OpenFold3 offered commercially usable co-folding capabilities for protein-ligand and antibody-antigen complexes. Boltz-2, an open-source biomolecular foundation model from MIT and Recursion, achieved near-physics-level accuracy for binding affinity predictions at speeds up to 1,000 times faster than traditional approaches.

3.3 Implications for Longevity

For the longevity field, the implications are monumental. Traditionally, taking a drug from initial discovery to regulatory approval requires 12 to 15 years and costs approximately 2.5 billion dollars. AI promises to dramatically compress both parameters. Specifically for anti-aging therapies:

First, target identification. The molecular processes of aging involve hundreds of proteins interacting in complex networks. AlphaFold and derived models make it possible to visualize these interactions at atomic resolution, identifying points of vulnerability — binding sites, interaction interfaces, allosteric regions — that can be exploited therapeutically.

Second, molecule design. Generative AI models can design molecules de novo with desired properties: high affinity for a specific target, low toxicity, good oral bioavailability, metabolic stability. The total chemical space of pharmacologically relevant molecules is estimated at 10^60 compounds — more than the number of atoms in the observable universe. Without AI, exploring this space is impossible. With generative AI, it becomes tractable.

Third, side-effect prediction. Cellular reprogramming therapies carry significant oncogenic risks. AI models trained on multi-omic data can predict which combinations of factors, doses and durations minimize risks while maximizing rejuvenation — a multi-objective optimization problem that exceeds the human capacity for intuitive reasoning.

IV. Deep Epigenetic Clocks: AI as an Instrument for Measuring Aging

4.1 The Problem of Measurement

One of the most fundamental barriers to the science of longevity is the absence of a reliable, real-time metric of biological aging. If we cannot measure precisely how aged an organism is, we cannot assess whether an intervention works without waiting decades — the time needed to observe differences in morbidity and mortality.

Epigenetic clocks, originally developed by Steve Horvath in 2013, offered the first practical solution. Using regularized regression (Elastic Net) on DNA methylation patterns at selected CpG sites, the Horvath clock predicts chronological age with a mean absolute error of a few years. The divergence between chronological age and estimated epigenetic age — called “epigenetic age acceleration” — correlates with mortality, cardiovascular disease, cancer and multiple other adverse outcomes.

But first-generation clocks have significant limitations. They assume linear relationships between methylation and age. They do not distinguish between causal and adaptive changes. And they do not capture complex nonlinear interactions among CpG sites — interactions that probably encode biologically meaningful information about the aging process.

4.2 Deep Learning and the New Generation of Clocks

The application of deep neural networks to biological age prediction has produced the so-called “Deep Aging Clocks,” which consistently outperform linear models in accuracy and generalization. AltumAge, a neural-network-based framework trained on 142 publicly available datasets from multiple human tissues, shows superior performance to Elastic Net for both intra-dataset and cross-dataset prediction, being particularly more generalizable at advanced ages and in new tissue types.

More recently, XAI-AGE introduced an approach of biologically informed, explainable deep neural networks. By integrating prior biological network information into the model architecture, XAI-AGE not only predicts age with high accuracy, but allows biologically meaningful insights to be inferred about the processes that control aging. This model opened the possibility of identifying specific molecular pathways — not just statistical correlates — that govern the acceleration or deceleration of aging.

NCAE-CombClock achieved R² = 0.978 with a mean absolute error of 1.96 years, integrating data-driven DNA methylation embeddings with established age-related CpG markers. Associated neural classifiers can classify individuals at critical developmental ages with AUROCs above 0.92.

In 2024, Gladyshev and collaborators at Brigham and Women’s Hospital published in Nature Aging the CausAge, DamAge and AdaptAge clocks — the first generation of epigenetic clocks that distinguish between causal changes of aging and protective adaptations. Using causal inference and machine learning techniques, these clocks created a map identifying human CpG sites that cause biological aging, making it possible to assess how different interventions promote longevity or accelerate aging. DamAge correlated with mortality; AdaptAge, with longevity.

4.3 Multimodal Clocks and the Frontier

The frontier of aging clocks is markedly multimodal. FaceAge, a deep learning system published in The Lancet Digital Health in 2025, estimates biological age from facial photographs to improve clinical prognosis. Systems based on chest X-rays, electrocardiograms and microbiome data demonstrate that aging leaves detectable signatures in practically any modality of biological data — and that neural networks are the most sensitive instruments for detecting them.

The implication for the science of longevity is twofold. First, deep-learning-based epigenetic clocks serve as surrogate endpoints for clinical trials of anti-aging interventions, compressing the time needed to evaluate efficacy from decades to months or years. Second, the interpretability of these models — through explainable AI (XAI) techniques — is revealing molecular mechanisms of aging that remained hidden to traditional statistical methods.

A multi-view graph-level representation learning framework (MGRL) published in 2025 integrated single-cell RNA-seq data from more than a million immune cells from 981 donors with protein-protein interaction networks, revealing a subnetwork of ribosomal genes whose expression correlates with age independently of cell type. The same approach applied to DNA methylation data from purified monocytes revealed an epigenetically dysregulated inflammatory response pathway whose activity increases with age — involving cytokine signaling and JAK-STAT pathways, with deregulation mediated by DNA methylation in monocytes.

V. SENS, Longevity Escape Velocity and the Damage-Repair Strategy

5.1 De Grey’s Framework

Aubrey de Grey, the biogerontologist who coined the term “longevity escape velocity” (LEV) in 2004, proposed the SENS framework (Strategies for Engineered Negligible Senescence), which identifies seven main categories of aging damage, each requiring its own repair strategy: accumulation of intracellular and extracellular junk, nuclear and mitochondrial mutations, cellular senescence, cell loss and extracellular crosslinks.

The SENS approach is conceptually distinct from both Sinclair’s epigenetic approach and Church’s genomic engineering approach, although complementary to both. While Sinclair seeks to “reset” the cellular software and Church seeks to “rewrite” the genomic hardware, de Grey seeks to “fix” the accumulated damage — like a mechanic diagnosing and repairing an aging car.

In 2025, the LEV Foundation completed its first Robust Mouse Rejuvenation (RMR) study, obtaining what de Grey called a “qualified victory”: the combination of multiple damage-repair interventions in middle-aged mice demonstrated additive lifespan extension, indicating synergies in multi-therapeutic combinations. The last mouse died on February 12, 2025, and the final survival curves are being statistically analyzed.

5.2 LEV and the Role of AI

The concept of longevity escape velocity is essentially an argument about compounding rates of technological progress. If “SENS 1.0” therapies can add 30 years of healthy life to middle-aged people, those same people will be alive to receive “SENS 2.0,” which will add more time, and so on — accelerating until medical progress outpaces the speed of aging.

AI is the accelerator that can turn this concept from bold speculation into practical engineering. The combination of multiple anti-aging interventions — senolytic drugs, stem-cell therapies, gene therapies, epigenetic modulation, enzyme engineering — generates a combinatorial space that grows exponentially with each added modality. A 2025 study showed that rapamycin combined with the MEK inhibitor trametinib extended median lifespan by 27-29% in middle-aged mice of both sexes, surpassing the single agents (rapamycin: 17-18%; trametinib: 5-10%) through synergistic inhibition of growth signaling and senescence.

Identifying the optimal combinations among dozens of candidate interventions, each with multiple possible doses and time windows, is an optimization problem that only AI can solve in a timely way. Reinforcement learning models can navigate this parameter space, virtually testing billions of combinations and converging on optimal protocols before experimental validation.

De Grey predicts a 50% probability of reaching LEV around 2036. Kurzweil predicted something similar for 2028-2030 (revised in 2024 to 2029-2035). Church offers a more conservative estimate, suggesting that 2050 would not be surprising. Regardless of the specific timeline, all converge on one point: AI will be the decisive factor in the acceleration.

VI. Digital Biology: AI as Microscope, Telescope and Inference Engine

6.1 Spatial Transcriptomics and Anatomical Atlases

One of Church’s most ambitious projects is SAHA (Spatial Atlas of Human Anatomy), a multimodal human anatomical atlas with subcellular resolution. Spatial transcriptomics — the ability to measure which genes are being expressed at which spatial locations within a tissue — generates volumes of data that exceed by orders of magnitude what human scientists can analyze manually. Each tissue slide can contain millions of spatially resolved data points, each with expression profiles for thousands of genes.

AI is the analytical instrument that makes these data interpretable. Convolutional neural networks for image segmentation, graph neural networks for modeling spatial relationships among cells, and transformers for integrating multiple data modalities (transcriptomics, proteomics, metabolomics, imaging) converge to create computational models of tissue that capture biological organization at scales ranging from the molecule to the organ.

For longevity, this capability is transformative. Aging is not a uniform process: different cell types in different tissues age at different rates, with distinct functional consequences. A complete spatial atlas of human aging — showing how cellular composition, gene expression patterns and spatial organization change with age in each tissue — would provide the map needed to direct interventions with unprecedented precision.

6.2 Foundation Models for Biology

The emergence of “foundation models” for biological data is perhaps the most significant revolution at the intersection of AI and biology. Just as GPT-4 learned deep statistical patterns in human language, models such as ESM (Evolutionary Scale Modeling) learned the “grammar” of protein sequences, encoding decades of evolution into vector representations that capture functional and structural properties.

Protein language models can interpret the “grammar” of sequences, allowing not only structure prediction but the de novo design of proteins with specified functions. This opens the door to engineering new enzymes (such as the soil-bacteria enzymes that de Grey proposes for degrading intracellular junk), new transcription factors (safer and more efficient versions of the Yamanaka factors), and new delivery vectors (AAV variants computationally optimized to evade the immune system).

RoseTTAFold All-Atom, developed at the University of Washington, completed full all-atom biological modeling in 2024, enabling high-resolution predictions for complex biomolecular systems. The AI Structural Biology (AISB) network demonstrated a model in which pharmaceutical companies began fine-tuning AI models on proprietary structural data through federated learning, creating a path to pharma-grade models without sharing intellectual property.

6.3 Simulations and Digital Twins

The ultimate ambition of digital biology is the creation of digital twins — computational models of individuals that capture the complete biological state of an organism and make it possible to simulate the effects of interventions before implementing them physically. A digital twin of an elderly patient could predict how a specific combination of gene therapies, senolytic drugs and epigenetic modulators would affect each system of the body, identifying synergies and antagonisms, predicting side effects and optimizing personalized treatment protocols.

This vision is still far from complete realization, but each component is progressing rapidly. ML-accelerated molecular dynamics, multi-scale models integrating single-cell transcriptomics with protein interaction networks, and reinforcement-learning frameworks for treatment optimization are converging toward a capacity for biological simulation that would have been unthinkable a decade ago.

VII. Xenotransplantation, Engineered Organs and AI in the Biological Supply Chain

7.1 eGenesis and the Problem of Organ Scarcity

One of the companies co-founded by Church is eGenesis, focused on solving the shortage of organ donors through xenotransplantation — the transplantation of organs between species. Using CRISPR to edit the porcine genome, eliminating endogenous retroviruses and modifying immune-compatibility genes, eGenesis is developing pig organs compatible with the human immune system.

AI plays several roles in this program. First, in predicting which genomic edits minimize immune rejection while preserving the organ’s functional viability. Second, in optimizing multiplex editing protocols — eGenesis has carried out more than 60 simultaneous edits in porcine genomes, a number that exceeds the capacity of purely human rational design. Third, in post-transplant monitoring: ML models can detect early signs of rejection in biomarker data before they manifest clinically.

7.2 Bioprinting and Organoids

The 3D bioprinting of tissues and the culture of organoids (mini-organs derived from stem cells) represent approaches complementary to xenotransplantation. Both depend deeply on AI for optimization. Bioprinting requires precise control of hundreds of parameters (cell type, density, deposition speed, bio-ink composition, temperature, cross-linking), forming a parameter space that ML models navigate more efficiently than manual optimization.

The human ovarian organoid technology developed at the Wyss Institute and commercialized by Gameto exemplifies the convergence. Using the Wyss’s fully human ovarian organoid technology, the company aims to address the growing global problem of infertility by making IVF safer, more accessible and more effective. Optimizing the protocols for culture, differentiation and maturation of organoids is intrinsically an ML problem — with parameter spaces far too large for manual exploration.

VIII. Economic, Ethical and Civilizational Implications

8.1 The Economics of Radical Longevity

De Grey argues that the cost of longevity therapies to the end user will be effectively zero — and that the reason is purely economic: aging is so expensive that it would be economic suicide for any country not to make these therapies universally available, regardless of ability to pay. Adults over 50 already contribute 45 trillion dollars to global GDP, with projections suggesting this will more than double to 118 trillion dollars by 2050.

Formal economic analysis supports this argument. A National Academy of Medicine report argues that older, healthier populations turn from a fiscal challenge into a net economic asset. If people remain productive and healthy into their 90s or beyond, they continue to generate, consume and contribute to GDP. The longevity dividend is not merely the extension of years of life — it is the extension of productive, healthy years of life.

The market for AI in pharmaceuticals, valued at 1.8 billion dollars in 2023, is projected to reach 13.1 billion dollars by 2030, reflecting a compound annual growth rate of 18.8%. For the longevity subset, the numbers are even more striking: companies such as Altos Labs, New Limit and Retro Biosciences have attracted hundreds of millions in investment from prominent Silicon Valley names for research on cellular reprogramming.

But the economics of radical longevity goes beyond the market for therapies. Recent analyses estimate that the economic value of radically extending human life could reach 367 trillion dollars — more than current global GDP. This figure reflects not only the value of the therapies themselves, but the present value of the additional decades of economic productivity, innovation and consumption that healthy individuals with radically extended life expectancies would generate.

The insurance sector will be transformed in fundamental ways. Life insurance will have to pivot to “longevity insurance” — products that protect people against the risk of outliving their financial reserves, rather than paying death benefits. We are already seeing the emergence of longevity swaps and longevity bonds, in which insurers transfer to investors the risk of clients living longer than expected. If de Grey’s vision materializes, these hedging instruments will become essential to the sector’s survival.

Retirement systems will face the most immediate challenge. If people remain biologically young and productive at 80 or 90, the notion of retiring at 60-65 becomes economically absurd. The social contract between generations — in which active workers fund inactive retirees — will have to be fundamentally renegotiated. This is not necessarily negative: people who want to work (and can, because they have been rejuvenated) are a resource, not a burden. But the transition will be disruptive for institutional structures that assume a fixed life expectancy.

8.2 Non-Trivial Ethical Questions

Radical life extension raises ethical questions that transcend the simplistic utilitarian framework. Who will have access first? If therapies cost millions of dollars at the outset, will radical longevity deepen inequalities that are already obscene? De Grey’s economic argument — that the costs of aging are so high that universal availability is economically rational — is optimistic but not guaranteed.

There is also the question of personal identity. If we can “reset” cells to a younger state, in what sense is the rejuvenated person the same person? Church’s neuronal “Ship of Theseus” — the gradual replacement of aging neurons with new ones that learn the existing circuit — raises philosophical questions about the continuity of consciousness that are not merely academic if the technology becomes real.

And there is the ecological question. A planet with 8 billion humans is already under extreme environmental stress. If life expectancy doubles or triples without a corresponding reduction in birth rates, pressures on natural resources, carbon emissions and ecosystems intensify dramatically. The longevity community’s standard response — that people with longer time horizons take better care of the planet — is plausible but empirically untested.

8.3 The Regulatory Question

The FDA still does not classify aging as a disease, which means that anti-aging interventions must be approved on the basis of specific indications (glaucoma, sarcopenia, Alzheimer’s disease) rather than “aging” as a treatable condition. Sinclair’s Life Biosciences obtained FDA approval to proceed with the first targeted age-reversal clinical trial in human volunteers, treating eye disease with reprogramming — but under the heading of a specific medical condition, not of aging itself.

In January 2026, Life Biosciences confirmed the start of the first human trials of a rejuvenation method. The approach uses OSK factors to reprogram ocular cells to a healthier state. But competing companies such as New Limit (which conducted an extensive search for alternative reprogramming factors) and Shift (whose animal experiments are only beginning) question whether the specific factors chosen are the best version of rejuvenation available.

IX. GPT-4b Micro and Protein Engineering by Generative AI: The Retro Biosciences Case

9.1 The Redesign of the Yamanaka Factors

Perhaps no recent result better illustrates the convergence of AI and longevity than the collaboration between OpenAI and Retro Biosciences, announced in August 2025. Using GPT-4b micro — OpenAI’s first model trained specifically for biological data, combining protein sequences, structural data and contextual annotations such as evolutionary relationships and functional descriptions — the Retro team redesigned variants of the transcription factors SOX2 and KLF4, two of the four Yamanaka factors central to cellular reprogramming.

The results were remarkable. The engineered variants — called RetroSOX and RetroKLF — showed an increase of more than 50-fold in the expression of stem-cell markers compared with wild-type controls. In some experiments, the generation of iPSCs (induced pluripotent stem cells) was accelerated from three weeks to just seven days. More than 30% of the AI-generated SOX2 variants outperformed the natural protein in initial screens, while nearly half of the KLF4 variants showed superior activity.

The most significant aspect for longevity is not just the efficiency of reprogramming, but the quality of the resulting cellular rejuvenation. Using a DNA-damage assay, the researchers found that cells treated with the RetroSOX/KLF cocktail accumulated significantly fewer DNA double-strand breaks than those reprogrammed with the original Yamanaka factors. This reduction suggests that the AI-engineered variants may be more effective at reversing DNA damage — a central hallmark of aging.

9.2 The Magnitude of the Sequence Change

One particularly surprising technical detail: the most effective RetroSOX and RetroKLF variants differed significantly from their wild-type counterparts, with some containing more than 100 amino acid changes. This is a result that no traditional protein-engineering program — based on site-directed mutagenesis, directed evolution or human rational design — would have produced. Generative AI explored regions of protein sequence space that lay completely beyond the cognitive reach of human scientists, finding solutions that work better than billions of years of natural evolution.

This result has profound implications. If AI can redesign transcription factors with 100+ mutations and obtain functionally superior proteins, the same principle can be applied to virtually any therapeutic protein relevant to longevity: enzymes for degrading lipofuscin (de Grey’s intracellular “junk”), molecular chaperones for maintaining proteostasis, modified telomerases for telomere maintenance, and growth factors optimized for tissue regeneration.

9.3 The Competitive Ecosystem of 2025-2026

The competitive landscape of longevity in 2025-2026 reflects the centrality of AI to the field. Altos Labs, founded in 2022 with 3 billion dollars in initial funding (the most heavily funded biotech startup in history), backed by Jeff Bezos and with Shinya Yamanaka as scientific advisor, reported the start of initial human safety trials in August 2025. Retro Biosciences, backed by OpenAI CEO Sam Altman with a 180-million-dollar seed round, is raising a 1-billion-dollar Series A at a 5-billion-dollar valuation. NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised 130 million in a Series B, focusing on an extensive search for alternative reprogramming factors. Shift Biosciences, based in Cambridge, UK, used machine learning to find safer and more efficient reprogramming genes.

Sinclair’s Life Biosciences obtained IND (Investigational New Drug) approval from the FDA for ER-100, becoming the first cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials. The phase 1 study will include individuals with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.

In parallel, Retro Biosciences dosed the first participant in a clinical trial of its autophagy-focused candidate, RTR242 — a small-molecule therapy designed to restore lysosomal function. The phase 1 study, randomized, double-blind and placebo-controlled in healthy volunteers, is being conducted in Adelaide, Australia, where early-stage approvals are faster. The study includes exploratory biomarkers linked to autophagy and lysosomal biology, giving Retro its first opportunity to observe whether its mechanistic hypotheses translate into measurable biological signals in humans.

9.4 AI as a Systemic Accelerator

What emerges from this landscape is not merely the occasional use of AI on isolated problems, but AI as a systemic accelerator of the entire longevity pipeline. AI is being used simultaneously to: identify targets (computational transcriptomics, GWAS with machine learning), design molecules (generative models), optimize reprogramming protocols (GPT-4b micro), predict safety (predictive models of oncogenicity), design clinical trials (adaptive statistical optimization), and analyze trial data (automated biomarker interpretation).

The combination of these uses creates a multiplicative effect: each improvement in one stage of the pipeline accelerates all subsequent stages. AI is not adding value linearly — it is exponentially compressing the time between discovery and clinic.

X. The Question of the Biological Feedback Loop: Organisms as Control Systems

10.1 Homeostasis and Aging

A frequently neglected perspective in the discussion of AI and longevity is the understanding of aging as the progressive failure of control systems. Biological organisms are, fundamentally, feedback control systems: sensors detect deviations from desired states, controllers process this information, and actuators execute corrections. Homeostasis — the maintenance of body temperature, blood pH, blood pressure, hormone levels — is implemented by biochemical feedback circuits operating on multiple time scales.

Aging can be understood as the progressive degradation of these control circuits: sensors lose sensitivity (molecular receptors accumulate damage), controllers lose precision (cellular signaling becomes noisy), and actuators lose effectiveness (effector cells become senescent or dysfunctional). Sinclair’s epigenetic information, from this perspective, is the “firmware” of the controllers: when it degrades, the system loses the capacity to maintain optimal physiological states.

AI is particularly well suited to modeling and optimizing control systems. Techniques of optimal control, reinforcement learning and dynamical-systems modeling are mature tools in control engineering that can be applied directly to the biology of aging. A computational model that captures the dynamics of homeostatic circuits — including their modes of failure with age — could predict which interventions restore control function most efficiently.

10.2 Cellular Senescence as a Bifurcation in a Dynamical System

Cellular senescence — the irreversible transition of proliferative cells to a state of cell-cycle arrest with a pro-inflammatory secretory phenotype (SASP) — can be modeled as a bifurcation in a dynamical system. Before the bifurcation, stochastic perturbations (DNA damage, oxidative stress) are absorbed by the cell’s control system; afterward, the system moves to an alternative stable attractor (the senescent state) from which it does not spontaneously return.

This dynamical-systems perspective suggests that AI could be used not only to eliminate senescent cells (the senolytic approach) or to reverse their state (reprogramming), but to identify “early warning signals” — molecular signatures indicating that a cell is approaching the senescence bifurcation, allowing preventive intervention before the transition occurs. Deep learning models trained on single-cell transcriptomic data with temporal resolution could detect these precursors with a sensitivity impossible for human analysis.

10.3 Regulatory Networks and Robustness

Aging can also be understood as a loss of robustness in gene regulatory networks. Young biological networks are highly redundant and tolerant of perturbations; aged networks lose redundancy and become fragile — susceptible to cascading failures in which the collapse of one component propagates rapidly through the network.

Graph neural networks (GNNs) and graph diffusion models are the natural tools for analyzing this loss of robustness. By mapping the topology of regulatory networks at different ages and in different tissues, and by identifying which nodes and connections are most vulnerable to aging, AI can guide interventions that restore topological robustness — for example, by reinforcing weakened redundancy pathways or stabilizing hub nodes that are critical to the integrity of the network.

XI. Computational Regenerative Medicine: From Prediction to Prescription

11.1 The AI-Accelerated DBTL Cycle

Modern biological engineering operates under the Design-Build-Test-Learn (DBTL) paradigm: design a genetic construct or molecule, build it in the laboratory, test it in biological systems, and learn from the results to inform the next design cycle. AI is compressing each stage of this cycle.

In design, generative models produce optimized candidates in silico. In building, automated laboratory robots execute protocols with a precision and throughput impossible for human hands. In testing, high-content phenotyping platforms generate multidimensional data on thousands of conditions simultaneously. In learning, active-learning algorithms select the next experiments so as to maximize the information obtained per unit of cost.

The result is a compression of the DBTL cycle from months to days. For longevity, this means that the search for optimal therapeutic combinations — which under the traditional experimental paradigm would take centuries — becomes feasible in years.

11.2 Autonomous Laboratories and Robot Scientists

The emerging frontier is the “autonomous scientist” (self-driving lab) — an integrated system in which AI not only analyzes data but formulates hypotheses, designs experiments, instructs robots to execute them, analyzes results and iterates. Several prototypes already exist for chemistry and materials science; extending them to the biology of aging is a matter of infrastructure integration, not of principle.

An autonomous laboratory dedicated to longevity could, in theory, carry out thousands of cellular reprogramming experiments per day, testing variations of factors, dosages, timings and combinations, feeding the results into models that refine themselves continuously. The discovery cycle that took Sinclair years — from the concept of OSK reprogramming to the first experiment in mice — could be compressed to weeks.

11.3 Digital Therapeutics and Personalized Interventions

The convergence of deep epigenetic clocks, personalized multi-omic data and predictive AI models enables a radically new form of medicine: personalized anti-aging interventions, in which the protocol is computationally optimized for each individual’s specific biological profile.

Instead of a generic “one dose fits all” therapy, AI could prescribe personalized combinations of senolytics, epigenetic modulators, growth factors and metabolic interventions, calibrated to each patient’s specific pattern of accumulated damage, genomic profile, immune status and environmental conditions. The deep epigenetic clock would serve simultaneously as a diagnostic (measuring the state of aging) and as an endpoint (assessing the efficacy of the intervention).

This vision is no longer purely speculative. Companies such as Insilico Medicine already use AI to identify therapeutic targets and design personalized molecules, with candidates in clinical trials. Extending this to personalized longevity is an incremental step, not a conceptual leap.

XII. The Limits of Optimism: Technical and Epistemological Critiques

12.1 The Mouse-to-Human Translational Gap

No honest discussion of AI and longevity can ignore the translational gap. Mice are not small humans. Differences in metabolism (mice have much higher basal metabolic rates), in genetics (isogenic laboratory strains do not reflect human genetic diversity) and in environmental exposures (laboratory mice live in controlled environments radically different from human life) limit the direct transposition of results.

De Grey explicitly acknowledges this limitation, arguing that dogs — whose life cycles and environments are closer to those of humans — are more informative intermediate models. Church also prioritizes canine models for analogous reasons. But definitive validation requires human trials, which are intrinsically slow (even with epigenetic clocks as surrogate endpoints) and expensive.

AI can partially mitigate this gap through computational models of cross-species translation — cross-species transfer learning that identifies which findings in mice are most likely to translate to humans. But it cannot eliminate it. Human biology, in all its idiosyncrasy, remains the final tribunal.

12.2 The Critique of the Information Theory

Sinclair’s Information Theory of Aging, although elegant and empirically supported by remarkable results, is not universally accepted. A UC San Diego study argues that somatic mutations — not epigenetic drift — may be the root cause of aging, suggesting that Sinclair’s focus on reversing epigenetic markers could be addressing symptoms rather than the underlying biology. If aging is fundamentally caused by the accumulation of mutations in genomic DNA (the digital information, not the analog), then epigenetic restoration would be palliative, not curative.

Sinclair’s response — that the reprogramming results demonstrate functional, not merely cosmetic, restoration of aged tissues — is persuasive but not conclusive. The question remains empirically open, and it is plausible that aging results from multiple interacting causes (epigenetic and genomic and mitochondrial and proteostatic), none of which is in itself “the” cause.

12.3 Oncogenic Risks of Reprogramming

The most serious risk of cellular reprogramming therapies is carcinogenesis. The Yamanaka factors are, by definition, pluripotency factors — and uncontrolled pluripotency is cancer. The inclusion of c-Myc (a known oncogene) in the original OSKM quartet was abandoned by many researchers precisely because of this risk. But even the OSK trio carries dangers: prolonged expression can revert cells completely to a stem-cell state, losing tissue identity and potentially initiating tumors.

AI can help calibrate dosages and durations to minimize risks, but it cannot eliminate them as long as the fundamental mechanism involves activating pluripotency pathways. Alternative approaches — such as the small molecules Sinclair is pursuing, or the proprietary factors New Limit is identifying — may offer superior safety profiles, but they remain at early stages of validation.

12.4 Hyperbole and the Track Record

An honest assessment requires mentioning that the science-communication record of some of the field’s protagonists includes significant controversies. Claims of supplement benefits that proved to lack adequate clinical evidence, acquisitions of hundreds of millions based on molecules that failed in trials, and projections of timelines that are systematically optimistic relative to what biology allows — all of this is part of the historical record. The data published in Nature and Cell on reprogramming are robust and replicated. But projections extrapolated on podcasts and at conferences should be evaluated with a skepticism proportional to their ambition.

XIII. Original Propositions: Six Theses on AI, Longevity and the Future of the Human Condition

Up to this point, this essay has reviewed the state of the art. Allow me now to propose six original theses that, I believe, capture underappreciated aspects of the convergence of AI and longevity.

Thesis 1: AI Is the “Leeuwenhoek Microscope” of Interventive Gerontology

Before Leeuwenhoek, microbiology could not exist as a discipline — not because microorganisms did not exist, but because we could not see them. Likewise, the biology of aging remained descriptive and correlational for decades because we lacked instruments to navigate the causal complexity of aging biological systems. AI is that instrument. Deep epigenetic clocks are not mere prediction tools — they are measuring instruments that make visible what was previously invisible: the rate, the trajectory and the causal mechanisms of biological aging at cellular and molecular resolution.

Thesis 2: The Real Bottleneck Is Not Computational but Experimental

Although AI has dramatically compressed the hypothesis-prediction cycle, the bottleneck of longevity science is shifting toward experimental validation. We can generate trillions of candidate molecules in silico, but testing them in real biological systems — cell cultures, organoids, animal models, clinical trials — remains slow and costly. The next frontier is no longer AI for generating hypotheses, but AI for automating experimentation: autonomous laboratory robots, automated cell cultures, high-throughput phenotyping integrated into closed active learning loops in which the AI decides which experiments to run next.

Thesis 3: Radical Longevity Requires Composite AI, Not Monolithic AI

No single AI model, however powerful, will solve the problem of aging. Aging is a multi-scale process (from molecule to organism), multi-temporal (from nanoseconds of molecular dynamics to decades of damage accumulation) and multi-modal (genomic, epigenomic, transcriptomic, proteomic, metabolomic, imaging). The AI architecture required is intrinsically composite: neural networks for structure prediction, generative models for molecular design, graph neural networks for interaction networks, causal models for mechanistic inference, reinforcement learning for protocol optimization, transformers for multi-omic integration, multi-agent systems for coordinating autonomous research. Composite AI — not monolithic AI — is the natural architecture for the longevity problem.

This thesis deserves elaboration. The concept of Composite AI — the deliberate integration of multiple AI paradigms (machine learning, symbolic reasoning, rule-based systems, optimization, simulation) into architectures that exploit their complementarities — is precisely what the longevity problem demands. Consider the chain of reasoning required to design a rejuvenation therapy:

First, one must identify molecular targets of aging — a causal-inference problem that requires sophisticated statistical models combined with prior knowledge encoded in biological ontologies and interaction networks. Second, one must design molecules that interact with those targets — a generative problem that requires diffusion models or transformers trained on chemical spaces. Third, one must predict the pharmacokinetics and toxicity of those molecules — a multivariate regression problem with a strong physical-simulation component (molecular dynamics). Fourth, one must optimize combination protocols — a multi-objective optimization problem with safety constraints that demands reinforcement learning. Fifth, one must design adaptive clinical trials — a sequential experimental-design problem that requires Bayesian inference. Sixth, one must interpret trial results in real time — an inference problem that combines clinical data with mechanistic models.

No AI paradigm solves all of these subproblems. Deep neural networks are excellent at structure prediction but poor at causal reasoning. Bayesian models are excellent at inference under uncertainty but limited in scale. Reinforcement learning is excellent at sequential optimization but requires reliable simulators. The solution is to compose — to create pipelines in which each component operates in its domain of competence, with interfaces that translate the outputs of one paradigm into inputs for the next.

More radically, multi-agent systems — in which agents specialized in different domains (one for structural biology, another for medicinal chemistry, another for regulatory affairs, another for clinical analysis) collaborate, negotiate and integrate their contributions — could replicate and eventually surpass the organization of human multidisciplinary teams, but at computational speed and scale. The analogy with biology itself is direct: organisms are not monolithic systems but ecosystems of specialized subsystems (immune, nervous, endocrine, metabolic) that coordinate to maintain homeostasis. AI for longevity should mirror this distributed biological architecture.

The Composite AI paradigm offers one further crucial advantage: explainability. By decomposing the pipeline into components with clear semantics, each decision can be traced back to the contribution of specific components — unlike a monolithic end-to-end model whose internal logic is opaque. For longevity therapies, where the risks are existential (literally — we are talking about life and death), the ability to explain why a specific therapeutic combination was recommended, what evidence supports each component of the recommendation, and what uncertainties remain is not a luxury — it is a regulatory and ethical necessity.

Thesis 4: The Convergence of AI and Longevity Will Create a New Kind of Epistemic Inequality

As longevity science becomes computationally intensive, the countries and institutions with the greatest AI capacity will obtain disproportionate advantages — not only in creating therapies, but in the fundamental understanding of the mechanisms of aging. This “epistemic inequality” is potentially deeper than inequality of access to therapies: if only a handful of laboratories in the world possess the computational infrastructure and the data needed to conduct frontier research on longevity, fundamental knowledge becomes oligopolized. The counter-pressure must come from open-source initiatives (OpenFold, AltumAge, the free AlphaFold Server) and from public computational infrastructure for science.

Thesis 5: Aging as “Bug” or “Feature” Is an Empirically Decidable Question, Not a Philosophically Undecidable One

The debate between those who see aging as an inevitable natural process and those who see it as a treatable disease is often framed as a philosophical or ethical question. But it is, fundamentally, an empirical one. If Sinclair’s Information Theory is correct — if aging is the degradation of epigenetic information, and if that information is restorable — then aging is a reversible process, and treating it as “natural and inevitable” is a factual error, not a legitimate philosophical position. AI, by making it possible to test this hypothesis with unprecedented rigor and scale, is turning a millennia-old philosophical question into an empirical research program with a resolution horizon on the scale of decades.

Thesis 6: “Longevity Escape Velocity” Is Better Understood as a Phase Transition in a Complex System

LEV is typically presented as a linear threshold: the point where annual medical progress exceeds the annual rate of aging. But I propose that it is more productive to conceptualize it as a phase transition in a complex adaptive system. The system includes not only medical technologies, but regulation, funding, clinical-trial infrastructure, public acceptance, manufacturing capacity and distribution networks. The transition occurs when positive feedback loops become dominant: successful longevity therapies generate revenue that funds more research; more powerful AI accelerates discoveries that generate data that improve the AI; rejuvenated individuals contribute economically, generating resources to rejuvenate more individuals. The role of AI in this framework is not only technical — it is catalytic: it is the agent that can synchronize and amplify multiple feedback loops simultaneously, precipitating the phase transition.

XIV. The Geopolitical Dimension: Who Will Control Longevity?

14.1 The Race Between Nations

Longevity science does not operate in a geopolitical vacuum. In 2025, China consolidated its position as a global power in early-stage pharmaceutical innovation: five of the ten largest R&D licensing deals of the year originated with Chinese companies, representing 38% of all in-licenses by large pharmaceutical firms with upfront payments above 50 million dollars. Two of these deals focused on AI-driven discovery platforms, including the 6-billion-dollar deal between Dovetree and XtalPi.

This geopolitical competition has direct implications for longevity. The ability to train AI models on massive biological datasets depends on computational infrastructure (cutting-edge GPUs, HPC clusters), proprietary data (population biobanks, digitized clinical records) and human capital (researchers trained at the intersection of AI and biology). Nations that accumulate advantages along these three dimensions — at present chiefly the United States and China, with Europe in an intermediate position — will have disproportionate influence over which therapies are developed, for which conditions, and at what price.

14.2 The Problem of Global Access

If radical longevity therapies emerge first at American and Chinese institutions, with initial costs in the range of millions of dollars (like Sinclair’s reprogramming gene therapy), the scenario of global access will be profoundly unequal. The first beneficiaries will be citizens of rich countries — precisely those who already have the longest life expectancies. The longevity gap between rich and poor nations, already a matter of decades, could turn into a civilizational gap.

De Grey’s counterargument — that the cost of sustaining aging populations is so high that governments will have an economic incentive to universalize therapies — is economically sound for countries with public health systems and fiscal capacity. For nations with precarious health systems and severe fiscal constraints, the argument is less convincing. Democratizing longevity will require not only scientific advances but institutional innovation: technology-transfer mechanisms, compulsory licensing and multilateral financing that ensure life-extension therapies do not become the deepest divider of inequality in human history.

14.3 The Question of Intellectual Property

The proprietary model exemplified by Isomorphic Labs — which developed a drug-discovery AI potentially superior to AlphaFold 3 but kept it as exclusive property — raises fundamental questions about who benefits from the convergence of AI and longevity. If the most powerful models for designing anti-aging therapies are proprietary, progress will be dictated by the commercial incentives of a handful of corporations. If they are open (like the original AlphaFold, OpenFold3, Boltz-2), progress will be faster, more diverse and potentially more equitable.

The tension between open and proprietary models in AI for longevity replicates the broader tension in the AI ecosystem. AlphaFold 2 was made freely available and used by 3 million researchers in 190 countries — including more than 1 million in low- and middle-income countries. This open-access model is one of the greatest contributions to the democratization of science in recent history. But Isomorphic Labs’ business model — and the fact that it is Isomorphic, not DeepMind’s academic arm, that is developing the most advanced capabilities — suggests that the frontier is moving behind proprietary walls.

XV. Philosophy of Technology: Longevity as a Civilizational Project

15.1 Church’s Meta-Technological Argument

George Church’s argument — that, given only one technology to develop, we should choose the one that gives us more time to develop all the others — deserves rigorous philosophical analysis. In its logical structure, it is a recursive argument about the instrumental value of time. If time is the fundamental scarce resource (not capital, not knowledge, not energy), then maximizing available time is meta-rationally optimal. Life extension, in this framework, does not compete with other technological projects — it is the prerequisite for all of them.

This argument has a logical form analogous to what in computer science is called “meta-optimization”: before optimizing any specific objective function, optimize the optimization process itself. Before solving any specific scientific problem, solve the problem of having enough time to solve problems. It is elegant, but it has implicit premises that deserve scrutiny.

The main premise is that more individual time translates into more civilizational progress. This is not obvious. Scientific revolutions often depend not on individuals working longer, but on new individuals bringing fresh perspectives. Kuhn argued that paradigms change not because practitioners of old paradigms are convinced, but because they die and are replaced by practitioners of new ones. Radical longevity could, paradoxically, slow scientific progress by entrenching paradigms and hierarchies.

The counter-response is that rejuvenated people would not be old people living longer — they would be biologically young people with accumulated experience, combining cognitive plasticity with wisdom. But this is an empirical prediction about the cognitive effects of biological rejuvenation that remains untested.

15.2 Philosophical Pessimism and Life Extension

There is a little-explored tension between philosophical pessimism (in the tradition of Schopenhauer, Cioran, Ligotti) and the project of life extension. If existence is fundamentally characterized by suffering, and if consciousness is the condition that makes suffering possible, then extending life is extending suffering. Schopenhauer would argue that the desire to live longer is precisely one more manifestation of the blind Will that perpetuates the cycle of desire and frustration.

But there is a transhumanist response to Schopenhauer that is worth articulating: the project of life extension is not merely quantitative (more years) but qualitative (better quality of life in all years). If biological rejuvenation eliminates chronic pain, functional decrepitude, dementia, loss of autonomy — the most acute forms of suffering associated with aging — then the hedonic balance of existence improves, not worsens. We are not extending suffering; we are extending the period during which avoidable suffering is avoided.

This response does not satisfy a consistent metaphysical pessimist. But it suggests that even within a pessimistic framework, the longevity project can be justified pragmatically: not as a metaphysical affirmation of the goodness of life, but as the engineering of reduced unnecessary suffering.

15.3 Personal Identity on the Horizon of Radical Longevity

If a person lives 200, 500 or 1000 years — with repeated cycles of biological rejuvenation — in what sense is the person of year 1 the same person as the person of year 500? Human psychology, memories, values, relationships — all of this transforms profoundly over decades. Over centuries, the transformation would be radical.

Derek Parfit argued that personal identity is not a binary relation (identical or non-identical) but a gradual one, based on psychological continuity and connectedness. On this analysis, a 500-year-old person would not be identical to the 20-year-old they once were — but would be connected to that person by an unbroken chain of gradual transformations. Just as an 80-year-old today is not “the same person” they were at 20 in any substantial sense, yet is connected to that person by continuity, a rejuvenated 500-year-old would maintain continuity without strict identity.

AI complicates this question in new ways. If brain-computer interfaces, external digital memories, or even gradual transfer of neural substrate (Church’s “Ship of Theseus”) enter the equation, the boundaries of personal identity will dissolve even further. Radical longevity is not only a question of biology — it is a question of philosophy of mind, and AI is at once the tool that makes the extension possible and the technology that most deeply challenges our notions of identity.

XVI. The State of the Art in 2026: A Map of the Terrain

16.1 Ongoing Clinical Trials

In January 2026, Life Biosciences confirmed the first targeted age-reversal attempt in human volunteers, using epigenetic reprogramming to treat eye disease. In parallel, senolytic drugs (such as dasatinib + quercetin) are in multiple phase II clinical trials for age-related conditions. Rapamycin and analogues are being tested for multiple geriatric indications. Rejuvenate Bio (co-founded by a former collaborator of Sinclair’s) is advancing longevity gene therapies, initially in dogs.

16.2 AI in the Longevity Pharmaceutical Pipeline

The market for AI-driven drug discovery is maturing rapidly. AI has graduated from point solutions to platform-scale discovery engines. For target-identification workflows, omics-based insights were combined with the expanded structural predictions of AlphaFold 3. OpenFold3 and Boltz-2 represent open-source alternatives that democratize capabilities previously restricted to large pharmaceutical companies. The AISB Network demonstrated that federated learning can create pharma-grade models without sharing proprietary data.

16.3 Critical Gaps

Despite remarkable progress, critical gaps remain. The translation of results from mice to humans remains uncertain — differences in metabolism, time scale and environmental factors limit direct applicability. The long-term safety of partial cellular reprogramming is unknown. Variability among human individuals is vastly greater than among isogenic mouse strains. And regulatory frameworks do not keep pace with the speed of the science — the FDA still does not recognize aging as a treatable indication.

XVII. Computational Neuroscience and Brain Aging: The Last Frontier

17.1 The Brain as a Special Case

Of all the dimensions of aging, brain aging is at once the most consequential and the most resistant to intervention. The brain is the only organ whose function depends critically on a specific configuration of connections — the connectome — that encodes decades of learning, memories and personality. Replacing aging neurons, unlike replacing cardiomyocytes or hepatocytes, carries the risk of destroying the information that defines who we are.

Church recognizes the brain as “the hardest part” of the rejuvenation program, but not as impossible. His proposal — artificially introducing stem cells that integrate into existing neuronal circuits, learn those circuits and gradually replace aging neurons — is a systems-engineering proposal that requires a computational understanding of the brain far beyond what we currently possess. For gradual neuronal replacement to preserve identity and function, it would be necessary to map the local connectome at synaptic resolution, understand how information is encoded in the topology of connections, and ensure that new neurons replicate not only the connections but the activity patterns of the neurons they replace.

17.2 AI as a Bridge to the Neuroscience of Aging

AI is advancing our understanding of brain aging on multiple fronts. Deep learning models applied to functional and structural magnetic resonance imaging data can detect patterns of brain aging with greater precision than clinical assessment. “Brain age” — the brain age predicted by AI from neuroimaging — has become an established biomarker, with brain age acceleration correlating with risk of dementia, cognitive decline and mortality.

More deeply, AI is enabling the analysis of spatial transcriptomic data from the brain — mapping which genes are expressed in which brain regions, in which cell types, and how those patterns change with age. Church’s SAHA project, combining subcellular resolution with coverage of multiple organs, promises to provide the most detailed atlas ever built of how the brain ages at the molecular and cellular level.

Graph neural networks applied to connectomics data — the mapping of the network of brain connections — can reveal how the topology of neuronal networks degrades with age. If certain topological properties (small-world efficiency, modularity, hub distribution) deteriorate in predictable and quantifiable ways, then AI could not only diagnose brain aging but guide interventions that restore optimal topological properties — whether through targeted brain stimulation, localized gene therapy, or, eventually, the gradual neuronal replacement Church proposes.

17.3 Brain-Computer Interfaces and Augmented Cognition

On the more distant horizon, high-bandwidth brain-computer interfaces (BCIs) could complement biological approaches to brain rejuvenation with computational ones. If individual neurons can be monitored and stimulated with precision — as the BRAIN Initiative and Neuralink aspire to — then dysfunctional neuronal circuits could be computationally “supplemented”: a neural prosthesis that compensates for the loss of function while biological therapies restore the substrate.

This is a speculative prospect, but not a fantastical one. Cochlear implants already realize a rudimentary version of this principle for the auditory system. Retinal prostheses do the same for vision. The extension to the cortical circuits involved in memory, attention and executive control — the functions most vulnerable to aging — is conceptually continuous, although technically formidable.

AI is central to any implementation of cognitive neural prostheses: decoding patterns of neural activity, identifying which circuits are dysfunctional, computing the stimulation patterns that restore function, and adapting in real time to changes in brain state. Church’s “Ship of Theseus” — the gradual replacement of neuronal substrate — may ultimately combine biological replacement (new neurons) with computational supplementation (BCIs) in a hybrid approach that neither technology could achieve alone.

17.4 The Final Convergence: Biology, Computation and Consciousness

There is a profound irony in the convergence of AI and longevity as applied to the brain: the same technology (AI) that we are using to understand and preserve biological consciousness is itself a form of information processing that raises questions about the nature of consciousness. If we manage to map, model and eventually restore neuronal circuits with enough fidelity to preserve memories and personality, what exactly are we preserving? The information? The substrate? Both?

The answer to this question has direct practical implications for the brain-longevity program. If personal identity is constituted by information (connection patterns, synaptic strength, dynamic states), then any substrate that faithfully preserves that information preserves the person. If identity requires the original biological substrate, then only rejuvenation in situ (without replacement) is acceptable. Empirical science — informed and accelerated by AI — will have to adjudicate between these philosophical positions, not through abstract argument, but through experimentation: rejuvenating brains and observing whether the person is preserved.

XVIII. Conclusion: The Engineering of Mortality

We are witnessing what may be the most consequential technological convergence in human history: the application of artificial intelligence to the understanding and potential reversal of biological aging. George Church offers the genomic engineering of whole organisms. David Sinclair offers the restoration of youthful epigenetic information. Aubrey de Grey offers the systematic repair of accumulated damage. AI — in its multiple forms: deep learning, generative models, reinforcement learning, graph neural networks, transformers, multi-agent systems — offers the computational substrate without which none of these programs could scale to the real complexity of human biology.

AlphaFold solved in a few years a problem that had resisted half a century. Epigenetic clocks based on deep learning are making aging measurable with unprecedented precision. Generative models are designing molecules that humans would never have conceived. Virtual screening systems are exploring chemical spaces larger than the number of atoms in the universe. Each of these achievements would be remarkable individually. Their convergence is potentially civilizational.

None of the researchers discussed in this essay — neither Church, nor Sinclair, nor de Grey — promises certainty. Church suggests that 2050 would be plausible for longevity escape velocity. De Grey bets on a 50% probability by 2036. Sinclair projects age-reversal pills within a decade. The timelines may be wrong — historically, optimistic biotechnology has often underestimated the time required. But the direction is unmistakable: AI is transforming longevity science from a philosophical aspiration into an engineering program.

The question that remains is not whether AI will contribute to the extension of human life — that is already happening, with every protein structure predicted, every molecule computationally designed, every epigenetic clock refined. The question is whether we are prepared — epistemically, ethically, institutionally — for the consequences of succeeding.

If Church is right that biology has “gifts” — levers it can hand us to pull — then AI is the instrument that allows us to identify and operate those levers with unprecedented precision. And if Sinclair is right that cells retain a backup copy of youthful epigenetic information, then AI is the reading mechanism that can restore that backup at scale.

The OpenAI-Retro Biosciences collaboration is perhaps the most potent symbol of this convergence: a generative AI company and a longevity company joining forces to redesign the fundamental proteins of cellular reprogramming, obtaining results that surpass billions of years of natural evolution. The RetroSOX and RetroKLF factors — each with more than 100 mutations relative to the wild-type proteins, working 50 times better — are a testament to what happens when computational power meets biological ambition.

But the next three to five years of human clinical-trial data — not social-media enthusiasm, not billion-dollar valuations, not podcast predictions — will determine whether epigenetic reprogramming marks the beginning of a medical revolution or yet another chapter in the history of biotechnology’s irrational exuberance. Life Biosciences’ trials with ER-100, Retro’s tests with RTR242, the programs of Altos Labs and NewLimit — each of these will produce concrete data that will confirm or refute decades of promises.

The role of AI in this period will be twofold. First, as an accelerator: compressing discovery timelines, optimizing protocols, identifying biomarkers, designing more efficient trials. Second, as an epistemic instrument: making visible what was invisible, measurable what was only estimable, tractable what was intractable. AlphaFold has not cured any disease directly — but by solving the protein structure prediction problem, it removed a bottleneck that limited all of structural biology and, by extension, all of drug discovery. Analogously, deep epigenetic clocks do not rejuvenate anyone directly — but by making aging precisely measurable, they remove the bottleneck that prevented the rapid evaluation of anti-aging therapies.

Ultimately, what is at stake is not just years of life, but quality of life, cognitive capacity, functional autonomy and human dignity in old age. AI for longevity science is not an exercise in Promethean hubris — it is, when conducted with rigor, caution and equity, one of the most deeply humanistic undertakings that technological civilization can pursue.

The history of science is, to a large extent, the history of instruments that expand human perception: telescopes that revealed planets, microscopes that revealed cells, sequencers that revealed genomes. Artificial intelligence is the next instrument in that lineage — but with a qualitative difference: it does not merely reveal what exists, but designs what could exist. It does not merely measure aging, but conceives solutions to reverse it. It does not merely observe biology, but redesigns it.

If the convergence of AI and longevity science produces even a fraction of what its most cautious proponents project — not thousand-year lives, but perhaps two or three more decades of healthy life for most humans — the impact will be civilizationally transformative. And if it produces what its boldest proponents imagine — longevity escape velocity, the obsolescence of aging as a cause of death — then we will have rewritten the human condition more deeply than any previous technology, including agriculture, writing and electricity.

In both scenarios, AI will have been the condition of possibility. Not the only condition — experimental biology, clinical infrastructure, political will, and ethical and regulatory frameworks are all equally necessary. But the condition without which the solution space would remain unnavigable, biological complexity would remain intractable, and the project of life extension would remain what it has been for millennia: a recurring dream of the species, articulated in myths and religions, but never translated into engineering.

That translation is under way. And what happens in the coming decades will determine whether our generation is remembered as the one that witnessed this transition or as the one that led it.

Aging is, by any metric, the greatest cause of human suffering on the planet — killing more than 100,000 people a day, every day, and degrading the quality of life of billions. Each year of delay in developing effective therapies represents 37 million additional deaths that could, in principle, have been prevented. The urgency is not rhetorical — it is arithmetic.

Artificial intelligence, by making the problem computationally tractable, has transformed longevity science from a discipline that could only describe aging into one that can, potentially, reverse it. That potential remains exactly that — potential. But for the first time in history, the distance between potential and realization is being measured in years and decades, not in centuries and millennia. And the tool that is compressing that distance is the same one that is revolutionizing every other domain of human knowledge: the ability of machines to find patterns, generate solutions and optimize processes at scales that radically transcend the biological cognition that created them.

Selected References

Sinclair, D.A. et al. “Reprogramming to recover youthful epigenetic information and restore vision.” Nature 588, 124–129 (2020).
Yang, J.-H. et al. “Loss of epigenetic information as a cause of mammalian aging.” Cell 186(2), 305–326.e27 (2023).
Jumper, J. et al. “Highly accurate protein structure prediction with AlphaFold.” Nature 596, 583–589 (2021).
Abramson, J. et al. “Accurate structure prediction of biomolecular interactions with AlphaFold 3.” Nature 630, 493–500 (2024).
de Grey, A.D.N.J. “Escape velocity: Why the prospect of extreme human life extension matters now.” PLoS Biology (2004).
Horvath, S. “DNA methylation age of human tissues and cell types.” Genome Biology 14, R115 (2013).
Ying, K. et al. “Causality-enriched epigenetic age uncouples damage and adaptation.” Nature Aging (2024).
de Magalhães, J.P. et al. AltumAge: “A pan-tissue DNA-methylation epigenetic clock based on deep learning.” npj Aging (2022).
Raj, A.P.M.S. et al. “Genetic signatures of exceptional longevity.” Human Genomics (2025).
Church, G.M. & Regis, E. Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves. Basic Books (2012).
de Grey, A.D.N.J. & Rae, M. Ending Aging. St. Martin’s Press (2007).
Sinclair, D.A. Lifespan: Why We Age — and Why We Don’t Have To. Atria Books (2019).
Levy, J.J. et al. “Insights to aging prediction with AI based epigenetic clocks.” Epigenomics 17(1), 49–57 (2025).
Scientific Reports. “Interpretable deep learning of single-cell and epigenetic data reveals novel molecular insights in aging.” Vol. 15, 5048 (2025).
Nature. “An AlphaFold 4: scientists marvel at DeepMind drug spin-off’s exclusive new AI.” 651, 18 (2026).

— comments